SEC Form 424B5 filed by Ocular Therapeutix Inc.
(To Prospectus dated September 30, 2025)
![[MISSING IMAGE: lg_oculartherapeutix-4clr.jpg]](https://www.sec.gov/Archives/edgar/data/0001393434/000110465925095006/lg_oculartherapeutix-4clr.jpg)
| | |
Per Share
|
| |
Total
|
| ||||||
Offering price
|
| | | $ | 12.53 | | | | | $ | 474,999,996 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.7518 | | | | | $ | 28,500,000 | | |
Proceeds, before expenses, to us
|
| | | $ | 11.7782 | | | | | $ | 446,499,996 | | |
| BofA Securities | | |
TD Cowen
|
| |
Piper Sandler
|
|
| Baird | | |
Raymond James
|
|
| Citizens Capital Markets | | |
H.C. Wainwright & Co.
|
|
| | |
Page
|
| |||
Prospectus Supplement
|
| | | | | | |
| | | | S-ii | | | |
| | | | S-iii | | | |
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-4 | | | |
| | | | S-5 | | | |
| | | | S-6 | | | |
| | | | S-10 | | | |
| | | | S-19 | | | |
| | | | S-19 | | | |
| | | | S-19 | | | |
| | | | S-19 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 17 | | | |
| | | | | 25 | | | |
| | | | | 28 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 33 | | | |
| | | | | 35 | | | |
| | | | | 35 | | |
offering
|
Offering price per share
|
| | | | | | | | | $ | 12.53 | | |
|
Historical net tangible book value per share as of June 30, 2025
|
| | | $ | 1.77 | | | | | | | | |
|
Increase in as adjusted net tangible book value per share attributable to new investors purchasing common stock in this offering
|
| | | | 1.80 | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | | 3.57 | | |
|
Dilution per share to new investors purchasing common stock in this offering
|
| | | | | | | | | $ | 8.96 | | |
Underwriter
|
| |
Number
of Shares |
| |||
BofA Securities, Inc.
|
| | | | 12,130,886 | | |
TD Securities (USA) LLC
|
| | | | 10,235,434 | | |
Piper Sandler & Co.
|
| | | | 7,960,894 | | |
Robert W. Baird & Co. Incorporated
|
| | | | 2,274,541 | | |
Raymond James & Associates, Inc.
|
| | | | 2,274,541 | | |
Citizens JMP Securities, LLC
|
| | | | 1,516,361 | | |
H.C. Wainwright & Co., LLC
|
| | | | 1,516,361 | | |
Total
|
| | | | 37,909,018 | | |
| | |
Per Share
|
| |
Total
|
| ||||||
Offering price
|
| | | $ | 12.53 | | | | | $ | 474,999,996 | | |
Underwriting discount
|
| | | $ | 0.7518 | | | | | $ | 28,500,000 | | |
Proceeds, before expenses, to us
|
| | | $ | 11.7782 | | | | | $ | 446,499,996 | | |
Attn: Chief Legal Officer and Corporate Secretary
15 Crosby Drive
Bedford, MA 01730
(781) 357-4000
![[MISSING IMAGE: lg_oculartherapeutix-4clr.jpg]](https://www.sec.gov/Archives/edgar/data/0001393434/000110465925095006/lg_oculartherapeutix-4clr.jpg)
Common Stock
Preferred Stock
Depositary Shares
Warrants
Units
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 17 | | | |
| | | | | 25 | | | |
| | | | | 28 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 33 | | | |
| | | | | 35 | | | |
| | | | | 35 | | |
Attn: Chief Legal Officer and Corporate Secretary
15 Crosby Drive
Bedford, MA 01730
(781) 357-4000
![[MISSING IMAGE: lg_oculartherapeutix-4clr.jpg]](https://www.sec.gov/Archives/edgar/data/0001393434/000110465925095006/lg_oculartherapeutix-4clr.jpg)
| Baird | | |
Raymond James
|
|
| Citizens Capital Markets | | |
H.C. Wainwright & Co.
|
|